Science 37 Holdings Inc (SNCE) - News Archive

The landscape of clinical trials is undergoing a transformative shift fueled by innovative digital strategies. This change is exemplified by Science 37 s remarkable contribution to GlaxoSmithKline s (GSK) Phase 3 rare d...

In a significant milestone for the decentralized clinical trials (DCT) landscape, Science 37 has been awarded the 2024 Global Company of the Year Award by Frost & Sullivan. This honor not only underscores Science 37’s p...

Science 37 Reinforces Clinical Trial Innovations with Cutting-Edge Research Facility in North Carolina s Research Triangle ParkIn a groundbreaking move for the clinical research industry, Science 37 has unveiled its new...

In the competitive world of clinical trials and healthcare research, one company has emerged as a standout performer. Science 37 Holdings Inc, a leader in decentralized clinical trials, has recently achieved some remark...

In an era where medical research and innovation are vital for advancing healthcare, clinical trials play a crucial role in bringing new therapies and treatments to patients. One persistent challenge in conducting clinic...

Clinical trials are vital for advancing medical knowledge and developing new treatments for various diseases. However, traditional trial structures often face challenges, particularly in enrolling patients with rare dis...

In an important achievement for virtual site quality assurance and compliance, Science 37 Metasite has passed a major regulatory endurance test by successfully undergoing an FDA inspection, marking a significant milesto...

Clinical trials are crucial for evaluating the safety and efficacy of new treatments, including those for asthma. Patient enrollment in trials is often a lengthy and costly process, impacting the timely development and...

In the race to develop groundbreaking medical treatments, clinical trials play a crucial role in assessing the effectiveness and safety of new therapies. However, one of the biggest challenges faced by researchers is en...

Science 37, a leading provider of virtual clinical trial operating systems, has recently announced that its stockholders will receive $5.75 per share in cash. The move comes as part of an acquisition deal with eMed, a c...

Science 37 Holdings, Inc., a leading Metasite company, recently announced the granting of inducement equity awards under their Employment Inducement Incentive Award Plan. This move indicates the company s commitment to...